Table 1 Patient characteristics

From: Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts

 

Study group add-back (n = 25)

Ctrl. group deplete (CD34+ PBSC) (n = 31)

Ctrl. group replete (BM) (n = 22)

Diagnosis

  ALL

9

16

13

  AML

5

7

5

  CML

2

6

2

  JMML

1

2

0

  NHL

3

0

0

  MDS (RAEB)

1

0

1

  MDS (RCC)

4

0

1

 Agea (years)

11 (0.5–18)

10 (1.5–24)

8.9 (2–17)

 Weighta (kg)

36 (6.8–90.6)

31 (9.6–98)

30 (13.7–73.3)

Disease status

  CR 1

5

4

5

  CR 2/3

10

16

12

  CP 1/2

3

5

2

  PR (NHL)

2

0

0

  AD

0

6

1

  REAB (MDS)

1

0

1

  RCC (MDS)

4

0

1

HLA match

  Matched

18

15

27

  Mismatched

    1 antigen

7

13

3

    2 antigens

0

3

0

Graft compositiona

  CD34+ cell purity

98.0%

98.5%

n.a.

 Cell dose

   CD34+ stem cells × 107/kgBW

1 (0.45–3)

0.8 (0.1–5.4)

n.a.

   CD3+ T cells × 107/kgBW

1.0007 (1.00009–1.0046)

0.0006 (0.00005–0.0034)

n.a.

  1. ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, CML chronic myelogenous leukemia, JMML juvenile myelomonocytic leukemia, NHL non-Hodgkin lymphoma, MDS myelodysplastic syndrome, RAEB refractory anemia with excess blasts, RCC refractory cytopenia of childhood, ID immunodeficiencies, IBE inborn errors, AA aplastic anemia, CR complete remission, CP D chronic phase disease, AD active disease, AP acute phase, n.a. not addressed, kgBW kg body weight
  2. aMedian (range)
Back to article page